Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Animal Mitochondrial Genetics02:59

Animal Mitochondrial Genetics

7.8K
Among all the organelles in an animal cell, only mitochondria have their own independent genomes. Animal mitochondrial DNA is a double-stranded, closed-circular molecule with around 20,000 base pairs. Mitochondrial DNA is unique in that one of its two strands, the heavy, or H, -strand is guanine rich, whereas the complementary strand is cytosine rich and called the light, or L, -strand. Compared to nuclear DNA, mitochondrial DNA has a very low percentage of non-coding regions and is marked by...
7.8K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

805
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

753
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: taxol- and thalidomide-induced injury of vasa nervorum is ameliorated by VEGF.

Molecular therapy : the journal of the American Society of Gene Therapy·2006
Same author

Intramuscular gene transfer of fibroblast growth factor-1 using improved pCOR plasmid design stimulates collateral formation in a rabbit ischemic hindlimb model.

Journal of molecular medicine (Berlin, Germany)·2006
Same author

Hyperhomocyst(e)inemia impairs angiogenesis in a murine model of limb ischemia.

Vascular medicine (London, England)·2005
Same author

Antiangiogenesis mediates cisplatin-induced peripheral neuropathy: attenuation or reversal by local vascular endothelial growth factor gene therapy without augmenting tumor growth.

Circulation·2005
Same author

Functional ephrin-B2 expression for promotive interaction between arterial and venous vessels in postnatal neovascularization.

Circulation·2005
Same author

Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor.

Circulation·2005

Related Experiment Video

Updated: May 1, 2026

Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice
09:00

Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice

Published on: August 2, 2018

7.8K

Myocardial gene therapy.

Jeffrey M Isner1

  • 1Department of Medicne, St. Elizabeth's Medical Center, Tufts School of Medicine, Boston, MA 02135, USA.

Nature
|January 24, 2002
PubMed
Summary
This summary is machine-generated.

Gene therapy shows promise as a safe and effective treatment for heart conditions like coronary artery disease and heart failure. Clinical trials suggest benefits from using angiogenic growth factors, with potential for functional improvement in patients.

More Related Videos

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
10:28

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

6.2K
A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

2.6K

Related Experiment Videos

Last Updated: May 1, 2026

Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice
09:00

Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice

Published on: August 2, 2018

7.8K
Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
10:28

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

6.2K
A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

2.6K

Area of Science:

  • Cardiovascular Medicine
  • Gene Therapy
  • Regenerative Medicine

Background:

  • Conventional treatments for coronary artery disease and heart failure have limitations.
  • Gene therapy presents a potential alternative for cardiovascular diseases.
  • Myocardial ischemia and heart failure are significant unmet clinical needs.

Purpose of the Study:

  • To evaluate the safety and efficacy of gene therapy for cardiovascular diseases.
  • To explore the potential of angiogenic growth factors in treating myocardial ischemia.
  • To assess the pre-clinical viability of gene therapy for heart failure.

Main Methods:

  • Phase 1 clinical trials were conducted to assess safety and benefits.
  • Gene therapy utilizing angiogenic growth factors was administered.
  • Pre-clinical studies investigated therapeutic angiogenesis via short-term gene expression.

Main Results:

  • Phase 1 trials demonstrated high safety and clinical benefits in myocardial ischemia.
  • Experimental data suggest functional improvement in heart failure models.
  • Therapeutic angiogenesis shows promise in pre-clinical heart failure research.

Conclusions:

  • Gene therapy is a viable alternative for coronary artery disease and heart failure.
  • Angiogenic growth factor gene therapy is safe and beneficial for myocardial ischemia.
  • Short-term gene expression for therapeutic angiogenesis may improve heart function.